Optimal dendritic-cell-based antitumor immunotherapy with cDC1 cells requires active mitochondria. Whereas vaccination with normal cDC1 cells efficiently reduces metastasis in B16-OVA tumors, the antitumor efficacy of these cells is diminished when their mitochondria are damaged.
    Research, Publications
    Science Immunology: Mitochondria control immune cell activation and the effectiveness of immunotherapy

    A CNIC-led study identifies a mitochondrial “checkpoint” that enables dendritic cells to efficiently activate T lymphocytes against viruses and tumors

    David Sancho, Ignacio Heras-Murillo y Stefanie Wculek.
    Research, Publications
    Mitochondria keep immune cells “ready to respond”

    Scientist at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and the Institute for Research in Biomedicine (IRB Barcelona) uncover a key metabolic mechanism governing immune cell readiness

    El Dr. David Sancho, junto a María Cid y Lola Manterola, de la Fundación Cris contra el Cáncer
    About the CNIC, Research
    CNIC-led project advancing a new ant-cancer strategy selected for the CRIS Excellence Program

    TARGET-DC, CNIC initiative led by Dr. David Sancho aims to identify novel immune checkpoints in dendritic cells to advance T-cell activation.

    Annalaura Mastrangelo
    About the CNIC, Research
    Researcher Annalaura Mastrangelo receives the 2026 Young Investigator Award in the Basic Science category
    •  
    • 1 of 5